FDA on Tuesday (April 21) cleared the first at-home diagnostic test for COVID-19 by re-issuing emergency use authorization to Laboratory Corporation of America’s (LabCorp’s) reverse transcriptase polymerase chain reaction test, which the agency says should be available in most states in the coming weeks. The authorization only applies to LabCorp’s COVID-19 test using the Pixel by LabCorp home collection kits. It is not a general authorization for at-home collection of patient samples using other collection swabs, media or tests or...